Physician profile
Thomas Dabrowski
NPI 1295148658
$895.28
in general payments reported to CMS, 2019-2025
15 companies · $298 in 2025
The $298 reported for 2025 was more than what 76% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $597 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $284.92 | 2024-2025 | Dovato, Apretude, Cabenuva |
| Organon LLC | $142.21 | 2024 | |
| Hologic Sales and Service, LLC | $105.28 | 2024-2025 | Aptima |
| Neurocrine Biosciences, INC. | $75.95 | 2024 | Ingrezza |
| Intuitive Surgical, INC. | $74.56 | 2025 | |
| Phadia US INC. | $31.89 | 2024-2025 | Immunocap |
| Philips North America LLC | $23.10 | 2025 | Extended Holter |
| Abbvie INC. | $22.81 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.17 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.05 | 2025 | |
| Exact Sciences Corporation | $20.71 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $19.05 | 2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $18.89 | 2024 | Mounjaro |
| Organogenesis INC. | $16.83 | 2024 | |
| Novo Nordisk INC | $14.86 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dabrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.